R21/Matrix-M
/ University of Oxford, Serum Institute of India
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
136
Go to page
1
2
3
4
5
6
June 13, 2025
Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
(PubMed, Vaccine)
- "The malaria vaccines, RTS,S/AS01 and R21/Matrix-M, bring fresh hope to curbing malaria mortality globally, especially among children below age five who are most susceptible...It draws from review-level evidence to propose four priority areas for improvement within the NPI to achieve a high-impact implementation-i.e., Reach Maximization, Social Mobilization, Program Management, and Progress Monitoring-in line with global immunization strategy frameworks. Evidence-based strategies to influence these domains in the Nigerian context are emphasized."
Journal • Infectious Disease • Malaria
June 09, 2025
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
(clinicaltrials.gov)
- P=N/A | N=2308 | Not yet recruiting | Sponsor: Serum Institute of India Pvt. Ltd.
New trial • Infectious Disease • Malaria
June 09, 2025
Infant Malaria Vaccine Schedule Optimization
(clinicaltrials.gov)
- P2 | N=1200 | Recruiting | Sponsor: PATH | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Malaria
April 26, 2025
Exploring the role of Plasmodium circumsporozoite-specific ZEB2+ cytolytic effector memory CD4+ T cells in protection against malaria
(IMMUNOLOGY 2025)
- "The two WHO-approved vaccines (RTS,S/AS01 and R21/Matrix-M) both target the circumsporozoite protein (CSP) antigen of the Plasmodium falciparum parasite...Using radiation-attenuated sporozoite immunization in ZEB2 reporter and loss-of-function mouse models, we are investigating if ZEB2+ CD4+ T cells differentiate, establish liver residency, and protect against live infection. Taken together, we will be discussing whether ZEB2+ CD4+ T cells may represent new correlates of protection in malaria.Keywords: Animals Human Rodent; Cells T Cells, Cytotoxic; Molecules T Cell Receptors; Processes Memory"
Infectious Disease • Malaria • CD4 • ZEB2
May 06, 2025
VAC093: A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
(clinicaltrials.gov)
- P1 | N=56 | Not yet recruiting | Sponsor: University of Oxford
New P1 trial • Infectious Disease • Malaria
May 06, 2025
Nurses' knowledge and willingness to recommend malaria vaccination to caregivers of under-5 in Nigeria: a nationwide survey.
(PubMed, Malar J)
- "The findings highlight major gaps in Nigerian nursing's knowledge and awareness of malaria vaccinations, as well as their willingness to recommend the vaccine to parents. Addressing these gaps will enable nurses to play a critical role in the successful implementation of malaria immunization campaigns, lowering the illness burden among vulnerable populations."
Journal • Infectious Disease • Malaria
April 26, 2025
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
(clinicaltrials.gov)
- P1 | N=240 | Active, not recruiting | Sponsor: Serum Institute of India Pvt. Ltd. | Trial primary completion date: Apr 2025 ➔ Oct 2025 | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Trial primary completion date • Infectious Disease • Malaria
April 21, 2025
First Malaria Vaccine RTS, S: A Step toward the Eradication of Malaria.
(PubMed, Arch Razi Inst)
- "RTS,S is a significant initial step in the path to the production of other highly protective and multi-stage vaccines that may become part of malaria eradication programs in the near future. Several malariologists are working on the early clinical development or trial phases of first-generation and next-generation malaria vaccines, such as R21/Matrix-M, using mRNA technology."
Journal • Infectious Disease • Malaria • Novel Coronavirus Disease
April 07, 2025
Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.
(PubMed, Clin Pharmacol)
- "The introduction of pre-erythrocytic malaria vaccines (RTS,S/AS01 and R21/Matrix-M), represents an important milestone in malaria control efforts with promising results from the erythrocytic vaccine RH5.1/Matrix-M in recent clinical trials...There is a critical need to integrate malaria vaccination efforts with established malaria control interventions (eg, insecticide-treated bed nets, vector control strategies, and anti-malarial drugs). Achieving sustained control of malaria morbidity and mortality will require strong global collaboration, sufficient funding, and continuous efforts to address inequities in access and delivery of malaria control measures including the malaria vaccines."
Journal • Review • Infectious Disease • Malaria
March 28, 2025
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
(clinicaltrials.gov)
- P1 | N=107 | Active, not recruiting | Sponsor: University of Oxford | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Malaria
March 17, 2025
Infant Malaria Vaccine Schedule Optimization
(clinicaltrials.gov)
- P2 | N=1200 | Not yet recruiting | Sponsor: PATH
New P2 trial • Infectious Disease • Malaria
March 19, 2025
Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
(PubMed, Vaccine)
- "The circumsporozoite protein (CSP) is a major surface protein of the sporozoites, and is the target of two licensed Plasmodium falciparum malaria vaccines, RTS,S/AS01, named Mosquirix and R21/Matrix-M. Low-dose passive transfer of the CL1 and CL3 antibodies conferred high-level protection when challenged with PfCSP-Pb transgenic parasites in the mouse infection model. The high in vitro and in vivo efficacies of the CL1 and CL3 antibodies have applications in malaria immunoprophylaxis in protecting travellers and military servicemen or as a therapeutic vaccine in malaria elimination programmes."
Journal • Infectious Disease • Malaria
March 05, 2025
IMVACS: Integrating Malaria Vaccine with Seasonal Malaria Chemoprevention in West Africa
(clinicaltrials.gov)
- P4 | N=40000 | Not yet recruiting | Sponsor: Epicentre
New P4 trial • Infectious Disease • Malaria
February 24, 2025
MVDA: Mass Vaccine and Drug Administration, Bangladesh
(clinicaltrials.gov)
- P4 | N=10000 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Malaria
February 20, 2025
A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults
(clinicaltrials.gov)
- P2 | N=80 | Terminated | Sponsor: University of Oxford | Phase classification: P2b ➔ P2 | Recruiting ➔ Terminated; Due to US FDA hold on the challenge agent and funding concerns
Phase classification • Trial termination • Infectious Disease • Malaria
February 08, 2025
Unlocking the potential of blood-stage vaccines for malaria elimination.
(PubMed, Trans R Soc Trop Med Hyg)
- "Currently, pre-erythrocytic vaccines like RTS, S/AS01 and R21/Matrix-M are in use, but their effectiveness is limited...Understanding the structural biology and immunological interactions of blood-stage antigens is essential for developing effective vaccines. Combining pre-erythrocytic and erythrocytic-stage vaccines could lead to better protection, improved public health outcomes and significant progress toward malaria elimination."
Journal • Infectious Disease • Malaria
February 04, 2025
Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.
(PubMed, BMJ Glob Health)
- "The R21/Matrix-M vaccine was acceptable to caregivers and communities of participants in the R21/Matrix-M phase III trial in Mali. Implementation research is needed to evaluate and ensure co-coverage of complementary malaria control interventions, including SMC in seasonal settings, in the face of the scale-up of R21/Matrix-M and other malaria vaccines."
Clinical • Journal • Infectious Disease • Malaria
January 26, 2025
The R21/Matrix-M malaria vaccine: questions remain.
(PubMed, Lancet)
- No abstract available
Journal • Infectious Disease • Malaria
January 26, 2025
The R21/Matrix-M malaria vaccine: questions remain.
(PubMed, Lancet)
- No abstract available
Journal • Infectious Disease • Malaria
January 26, 2025
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
(PubMed, Lancet)
- No abstract available
Journal • Infectious Disease • Malaria
January 26, 2025
The R21/Matrix-M malaria vaccine: questions remain.
(PubMed, Lancet)
- No abstract available
Journal • Infectious Disease • Malaria
January 19, 2025
Integrating malaria vaccine and CRISPR/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication.
(PubMed, Malar J)
- "Recent advancements, including the rollout of malaria vaccines, such as RTS,S/AS01 and R21/Matrix-M™, offer new avenues for prevention...Challenges such as regulatory hurdles, community acceptance, ecological impacts, and sustainable funding are examined, alongside strategies for implementation within existing malaria control programmes. This integrated approach could significantly contribute to achieving the World Health Organization's targets for malaria reduction by 2030, ultimately enhancing public health outcomes and supporting broader socio-economic development."
Journal • Review • Infectious Disease • Malaria
January 18, 2025
Roll out and prospects of the malaria vaccine R21/Matrix-M.
(PubMed, PLoS Med)
- "In this Perspective article, Lorenz von Seidlein outlines the promise of two malaria vaccines, and discusses some of the considerations for their roll out."
Journal • Infectious Disease • Malaria
January 14, 2025
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
(PubMed, Lancet Microbe)
- P1, P1/2 | "R21 with Matrix-M adjuvant has an acceptable safety profile. These data have formed the basis for efficacy testing of this vaccine."
Journal • P1 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Malaria • Rheumatology
January 14, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
(PubMed, Lancet Microbe)
- P1/2 | "Our study shows that R21/MM elicits high-level efficacy against clinical malaria in a controlled human infection model of malaria in adults who are malaria naive. These data supported the evaluation of R21/MM in field efficacy trials in the target population of young children in malaria-endemic areas."
Journal • P1/2 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Malaria
1 to 25
Of
136
Go to page
1
2
3
4
5
6